Related Experiment Video
Updated: Feb 11, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
R Pisters1, A Elvan2, H J G M Crijns3
1Department of Cardiology, Rijnstate Arnhem, Arnhem, The Netherlands.
Insights
Managing atrial fibrillation involves balancing stroke prevention with bleeding risks. This review emphasizes the optimal use of non-vitamin K antagonist oral anticoagulants (NOACs) for long-term stroke prevention in atrial fibrillation patients.
Area of Science:
- Cardiology
- Pharmacology
- Stroke Prevention
Background:
- Atrial fibrillation management requires balancing antithrombotic therapy to prevent thromboembolism and minimize bleeding.
- Non-vitamin K antagonist oral anticoagulants (NOACs) are now first-line for stroke prevention in non-valvular atrial fibrillation.
- Suboptimal adoption of previous therapies highlights the need for adequate NOAC utilization.
Purpose of the Study:
- To review and address key clinical challenges in the antithrombotic management of atrial fibrillation.
- To focus on the adequate use of NOACs for long-term stroke prevention.
- To optimize the antithrombotic life cycle management in atrial fibrillation.
Main Methods:
- Literature review focusing on antithrombotic management strategies.
- Analysis of clinical challenges in NOAC therapy for atrial fibrillation.
- Discussion of optimal antithrombotic life cycle management.
Main Results:
- NOACs are the preferred first-line therapy for stroke prevention in non-valvular atrial fibrillation.
- Addressing suboptimal adoption is crucial for effective antithrombotic therapy.
- Comprehensive management of the antithrombotic life cycle is essential.
Conclusions:
- Optimal antithrombotic management in atrial fibrillation necessitates a careful balance between efficacy and safety.
- Effective implementation of NOACs is key to improving stroke prevention in atrial fibrillation.
- Addressing clinical challenges ensures better long-term outcomes for patients.
Abstract:
Optimal antithrombotic management of atrial fibrillation equals balancing between prevention of arterial thromboembolism, predominantly ischaemic stroke, and haemorrhagic complications. Over time different antithrombotic agents and strategies have been developed. At present, non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy for stroke prevention in patients with non-valvular atrial fibrillation (i.e. without a mechanical valve prosthesis or rheumatic heart disease). Considering the impact of the suboptimal adoption of recommended oral anticoagulant therapy, as experienced with the previous first-line vitamin K antagonists, this review focuses on adequate use of NOACs. As such, we address the most important and clinically challenging issues in the antithrombotic life cycle management for long-term stroke prevention in atrial fibrillation.
Related Concept Videos
The Angiosperm Life Cycle
Retrovirus Life Cycles
Tonsillitis II: Management
Impression Management Techniques I: Managing Appearances
Managing Impressions
Management of Insomnia

